Olmetec and nighttime blood pressure in Korean adults with mild high blood pressure
Follows adults with high blood pressure taking Olmetec to see nighttime blood pressure changes.
Plain-language title generated from the registry record
Registry title: Observational Study to Evaluate the Efficacy of OLMETEC Tab on Nocturnal Blood Pressure Control in Patients With Stage Ⅰ Hypertension
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Multiple centers in Republic of KoreaSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daewoong Pharmaceutical Co. LTD.
- Trial code
- NCT07515599
- Record updated
- 7 April 2026
- Original description
This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.Read full original descriptionShow less
A Prospective, Multi-Center, Observational Study to Evaluate the Efficacy of OLMETEC Tab. (or OLMETEC Plus Tab.) on Nocturnal Blood Pressure Control in Korean Patients With Stage Ⅰ Hypertension
This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
Inclusion: Adults aged ≥19 years; Patients diagnosed with stage 1 hypertension according to clinical guidelines; Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice; Patients who are able to undergo ambulatory blood pressure monitoring (ABPM); Patients who voluntarily agree to participate and provide written informed consent.
Exclusion: Patients with secondary hypertension; Patients with severe hypertension requiring immediate pharmacological i-ntervention; Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs; Patients with severe renal impairment or severe hepatic impairment; Patients who are pregnant, planning to become pregnant, or breastfeeding; Patients who are unable to comply with study procedures, including ABPM; Patients who are deemed inappropriate for participation by the investigator.